Drug intelligence / Profile preview

META-2i

Development stage: Unknown
Lead developer: META Pharmaceuticals
Modality: Small Molecules

Overview

META-2i is a chemical drug under development by META Pharmaceuticals Inc. for the treatment of metabolic diseases. It is classified as a small molecule and is being developed for indications within endocrinology and metabolic disease. As of March 2025, its highest development phase is IND (Investigational New Drug) application in China, indicating it has not yet entered clinical trials or received regulatory approval. Specific details regarding its mechanism of action, molecular target(s), or pharmacological profile have not been disclosed publicly[6][10].

Beyond the preview

Go deeper on META-2i.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on META-2i.

Explore the full profile